Very informative post @NZ Trader and from one of the public write ups, Amylyx note
“Obtaining FDA Fast Track designation for AMX0114 is an important step forward in our mission to develop potential treatments for people living with ALS, a relentlessly progressive and fatal disease with limited therapeutic options,” said Camille L. Bedrosian, MD, Chief Medical Officer at Amylyx.
Note the emphasis on treatments i.e. the plural. I wonder if Amylyx will be at the BIO 2025....would make a nice fit and Amylyx's had cash, cash equivalents, and marketable securities of US$204.1 million as of March 31, 2025. What would an upfront ~$30 million mean to them for certain rights to NUZ-001???
NUZ Price at posting:
16.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)